SCIASCIA THOMAS 4
4 · Trevi Therapeutics, Inc. · Filed Mar 26, 2025
Insider Transaction Report
Form 4
SCIASCIA THOMAS
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-25$1.43/sh+2,631$3,762→ 224,004 total - Exercise/Conversion
Stock Option (right to buy)
2025-03-25−2,631→ 0 totalExercise: $1.43Exp: 2025-05-14→ Common Stock (2,631 underlying) - Sale
Common Stock
2025-03-25$6.60/sh−2,631$17,365→ 221,373 total
Footnotes (2)
- [F1]Includes 1,058 shares purchased through the Issuer's employee stock purchase plan.
- [F2]This option was granted on May 15, 2015. The 2,631 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019.